Xiaoyaosan slows cancer progression and ameliorates gut dysbiosis in mice with chronic restraint stress and colorectal cancer xenografts - 18/11/20



pages | 10 |
Iconographies | 7 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | XYS suppressed tumour growth and prolonged survival time in CRC mice with CRS. |
• | XYS protected the intestinal barrier of CRC mice with CRS. |
• | CRS-associated gut dysbiosis in CRC mice was improved by XYS treatment. |
Abstract |
Depression is a risk factor for colorectal cancer (CRC) progression. Xiaoyaosan (XYS) is a traditional Chinese medicine prescription for treating depression. Our present study aimed to investigate the effect of XYS on chronic restraint stress (CRS) in mice with CRC xenografts and explore its underlying mechanisms. XYS treatment for 21 consecutive days successfully reduced the tumour volume and tumour weight in mice and prolonged the overall survival time. In addition, the intestinal permeability in the XYS group was significantly improved after administration. The 16S rRNA high-throughput sequencing method was used to sequence stool samples to check the structure and changes of gut bacteria. XYS mainly regulated the abundance of Bacteroides, Lactobacillus, Desulfovibrio and Rikenellaceae. Taken together, these results provide direct strong evidence that XYS effectively improves the progression of CRC in CRS-handled mice, and its efficacy is associated with the modulation of gut dysbiosis. The application of XYS can be a novel therapeutic strategy for CRC patients with depression.
Le texte complet de cet article est disponible en PDF.Keywords : Xiaoyaosan, Chronic stress, Colorectal cancer, Depression, Gut Microbiota
Plan
Vol 132
Article 110916- décembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?